Current developments in the tissue engineering of autologous heart valves: Moving towards clinical use

Future Cardiology

Volumn 7, Issue 1, 2011, Pages 77-97

  Apte, Sameer S ^a   Paul, Arghya ^b   Prakash, Satya ^b   Shum Tim, Dominique ^a  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

heart valve prosthesis; stem cell; tissue engineered heart valve; valvular heart disease

Indexed keywords

POLYMER; TISSUE SCAFFOLD;

ARTICLE; AUTOTRANSPLANTATION; HEART VALVE REPLACEMENT; HUMAN; IN VIVO STUDY; MESENCHYME CELL; PRIORITY JOURNAL; PULMONARY VALVE REPLACEMENT; QUALITY OF LIFE; SURGICAL TECHNIQUE; TISSUE ENGINEERING; VALVULAR HEART DISEASE;

EXTRACELLULAR MATRIX; HEART VALVE DISEASES; HEART VALVE PROSTHESIS IMPLANTATION; HEMODYNAMICS; HUMANS; TISSUE ENGINEERING; TISSUE SCAFFOLDS; TRANSPLANTATION, AUTOLOGOUS; UNITED STATES;

EID: 78650665485     PISSN: 14796678     EISSN: 17448298     Source Type: Journal    
DOI: 10.2217/fca.10.120     Document Type: Article

References (145)

1. Lloyd-Jones D, Adams RJ, Brown TM, et al. Heart disease and stroke statistics - 2010 update: a report from the American Heart Association. Circulation 121(7), e46-e215 (2010).
2. Nkomo VT, Gardin JM, Skelton TN, et al. Burden of valvular heart diseases: a population-based study. Lancet 368, 1005-1011 (2006).
3. Ray S. Changing epidemiology and natural history of valvular heart disease. Clin. Med. 10(2), 168-171 (2010).
4. Sheikh AM, Livesey SA: Surgical management of valve disease in the early 21st Century. Clin. Med. 10(2), 177-181 (2010).
5. Yacoub MH, Takkenberg JJ. Will heart valve tissue engineering change the world? Nat. Clin. Pract. Cardiovasc. Med. 2(2), 60-61 (2005).
6. World Population Prospects: The 2008 Revision. Secretariat, United Nations, NY, USA (2008).
7. Sacks MS, Schoen FJ, Mayer JE: Bioengineering challenges for heart valve tissue engineering. Annu. Rev. Biomed. Eng. 11, 289-313 (2009).
8. Stock UA, Nagashima M, Khalil PN, et al. Tissue-engineered valved conduits in the pulmonary circulation. J. Thorac. Cardiovasc. Surg. 119(4 Pt 1), 732-740 (2000).
9. Rainer G: Interview with Dr. Dwight Harken, pioneer heart surgeon. In: Pioneer Interviews. The Cardiothoracic Surgery Network, MD, USA (2004).
10. Caceres-Loriga FM, Perez-Lopez H, Santos-Gracia J, Morlans-Hernandez K: Prosthetic heart valve thrombosis: pathogenesis, diagnosis and management. Int. J. Cardiol. 110(1), 1-6 (2006).
11. Rahimtoola SH: Choice of prosthetic heart valve in adults an update. J. Am. Coll. Cardiol. 55(22), 2413-2426 (2010).
12. Hammermeister KE, Sethi GK, Henderson WG, et al. A comparison of outcomes in men 11 years after heart-valve replacement with a mechanical valve or bioprosthesis. Veterans Affairs Cooperative Study on Valvular Heart Disease. N. Engl. J. Med. 328(18), 1289-1296 (1993).
13. Chambers JC, Somerville J, Stone S, Ross DN. Pulmonary autograft procedure for aortic valve disease: long-term results of the pioneer series. Circulation 96(7), 2206-2214 (1997).
14. Weymann A, Dohmen PM, Grubitzsch H, et al. Clinical experience with expanded use of the Ross procedure: a paradigm shift? J. Heart Valve Dis. 19(3), 279-285 (2010).
15. Alsoufi B, Al-Halees Z, Manlhiot C, et al. Superior results following the Ross procedure in patients with congenital heart disease. J. Heart Valve Dis. 19(3), 269-277; discussion 278 (2010).
16. Shinkawa T, Bove EL, Hirsch JC, Devaney EJ, Ohye RG: Intermediate-term results of the Ross procedure in neonates and infants. Ann. Thorac. Surg. 89(6), 1827-1832; discussion 1832 (2010).
17. Alsoufi B, Manlhiot C, Fadel B, et al. The Ross procedure in children: preoperative haemodynamic manifestation has significant effect on late autograft re-operation. Eur. J. Cardiothorac. Surg. 38(5), 547-555 (2010).
18. Frigiola A, Ranucci M, Carlucci C, et al. The Ross procedure in adults: long-term follow-up and echocardiographic changes leading to pulmonary autograft reoperation. Ann. Thorac. Surg. 86(2), 482-489 (2008).
19. Joyce EM, Liao J, Schoen FJ, Mayer JE Jr, Sacks MS. Functional collagen fiber architecture of the pulmonary heart valve cusp. Ann. Thorac. Surg. 87(4), 1240-1249 (2009).
20. Shi Y, Vesely I: Fabrication of mitral valve chordae by directed collagen gel shrinkage. Tissue Eng. 9(6), 1233-1242 (2003).
21. Flanagan TC, Wilkins B, Black A, et al. A collagen-glycosaminoglycan co-culture model for heart valve tissue engineering applications. Biomaterials 27(10), 2233-2246 (2006).
22. Okita Y, Miki S, Ueda Y, et al. Comparative evaluation of left ventricular performance after mitral valve repair or valve replacement with or without chordal preservation. J. Heart Valve Dis. 2(2), 159-166 (1993).
23. Shinoka T, Breuer CK, Tanel RE, et al. Tissue engineering heart valves: valve leaflet replacement study in a lamb model. Ann. Thorac. Surg. 60(Suppl. 6), S513-S516 (1995).
24. Shinoka T, Ma PX, Shum-Tim D, et al. Tissue-engineered heart valves. Autologous valve leaflet replacement study in a lamb model. Circulation 94(9 Suppl.), II164-II168 (1996).
25. Shinoka T: Tissue engineering heart valves: autologous cell seeding on biodegradable polymer scaffold. Artificial Organs 26(5), 402-406 (2002).
26. Sodian R, Hoerstrup SP, Sperling JS, et al. Early in vivo experience with tissue-engineered trileaflet heart valves. Circulation 102(19 Suppl. 3), III22-III29 (2000).
27. Hoerstrup SP, Sodian R, Daebritz S, et al. Functional living trileaflet heart valves grown in vitro. Circulation 102, 11144-11149 (2000).
28. Kim WG, Cho SK, Kang MC, Lee TY, Park JK: Tissue-engineered heart valve leaflets: an animal study. Int. J. Artif. Organs. 24(9), 642-648 (2001).
29. Sutherland FWH, Perry TE, Yu Y, et al. From stem cells to viable autologous semilunar heart valve. Circulation 111, 2783-2791 (2005).
30. Flanagan TC, Sachweh JS, Frese J, et al. In vivo remodeling and structural characterization of fibrin-based tissue-engineered heart valves in the adult sheep model. Tissue Eng. Part A 15(10), 2965-2976 (2009).
31. Gottlieb D, Kunal T, Emani S, et al. In vivo monitoring of function of autologous engineered pulmonary valve. J. Thorac. Cardiovasc. Surg. 139(3), 723-731 (2010).
32. Schmidt D, Dijkman PE, Driessen-Mol A, et al. Minimally-invasive implantation of living tissue engineered heart valves a comprehensive approach from autologous vascular cells to stem cells. J. Am. Coll. Cardiol. 56(6), 510-520 (2010).
33. Stamm C, Khosravi A, Grabow N, et al. Biomatrix/polymer composite material for heart valve tissue engineering. Ann. Thorac. Surg. 78, 2084-2093 (2004).
34. Steinhoff G, Stock U, Karim N, et al. Tissue engineering of pulmonary heart valves on allogenic acellular matrix conduits: in vivo restoration of valve tissue. Circulation 102(19 Suppl. 3), III50-III55 (2000).
35. Vincentelli A, Wautot F, Juthier F, et al. In vivo autologous recellularization of a tissue-engineered heart valve: are bone marrow mesenchymal stem cells the best candidates? J. Thorac. Cardiovasc. Surg. 134(2), 424-432 (2007).
36. Lutter G, Metzner A, Jahnke T, et al. Percutaneous tissue-engineered pulmonary valved stent implantation. Ann. Thorac. Surg. 89(1), 259-263 (2010).
37. Metzner A, Stock UA, Iino K, et al. Percutaneous pulmonary valve replacement: autologous tissue-engineered valved stents. Cardiovasc. Res. DOI: 10.1093/cvr/cvq212 (2010) (Epub ahead of print).
38. Dohmen PM, Hauptmann S, Terytze A, Konertz WF. In-vivo repopularization of a tissue-engineered heart valve in a human subject. J. Heart Valve Dis. 16(4), 447-449 (2007).
39. Dohmen PM, Lembcke A, Holinski S, et al. Mid-term clinical results using a tissue-engineered pulmonary valve to reconstruct the right ventricular outflow tract during the Ross procedure. Ann. Thorac. Surg. 84(3), 729-736 (2007).
40. Cebotari S, Lichtenberg A, Tudorache I, et al. Clinical application of tissue engineered human heart valves using autologous progenitor cells. Circulation 114, 132-137 (2006).
41. Gabbieri D, Dohmen PM, Linneweber J, et al. Ross procedure with a tissue-engineered heart valve in complex congenital aortic valve disease. J. Thorac. Cardiovasc. Surg. 133(4), 1088-1089 (2007).
42. Kunzelman KS, Grande KJ, David TE, Cochran RP, Verrier ED. Aortic root and valve relationships. Impact on surgical repair. J. Thorac. Cardiovasc. Surg. 107(1), 162-170 (1994).
43. Katayama S, Umetani N, Sugiura S, Hisada T: The sinus of Valsalva relieves abnormal stress on aortic valve leaflets by facilitating smooth closure. J. Thorac. Cardiovasc. Surg. 136(6), 1528-1535 (2008).
44. Grande-Allen KJ, Cochran RP, Reinhall PG, Kunzelman KS. Re-creation of sinuses is important for sparing the aortic valve: a finite element study. J. Thorac. Cardiovasc. Surg. 119(4 Pt 1), 753-763 (2000).
45. Tami LF, Turi ZG, Arbulu A: Sinus of Valsalva aneurysms involving both coronary ostia. Cathet. Cardiovasc. Diagn. 29(4), 304-308 (1993).
46. Mirnajafi A, Raymer JM, McClure LR, Sacks MS. The flexural rigidity of the aortic valve leaflet in the commissural region. J. Biomech. 39(16), 2966-2973 (2006).
47. Sacks MS, Smith DB, Hiester ED. The aortic valve microstructure: effects of transvalvular pressure. J. Biomed. Mater. Res. 41(1), 131-141 (1998).
48. Stella JA, Liao J, Sacks MS. Time-dependent biaxial mechanical behavior of the aortic heart valve leaflet. J. Biomech. 40(14), 3169-3177 (2007).
49. Stella JA, Sacks MS. On the biaxial mechanical properties of the layers of the aortic valve leaflet. J. Biomech. Eng. 129(5), 757-766 (2007).
50. Adamczyk MM, Lee TC, Vesely I: Biaxial strain properties of elastase-digested porcine aortic valves. J. Heart Valve Dis. 9(3), 445-453 (2000).
51. Lee TC, Midura RJ, Hascall VC, Vesely I: The effect of elastin damage on the mechanics of the aortic valve. J. Biomech. 34(2), 203-210 (2001).
52. Lo D, Vesely I: Biaxial strain analysis of the porcine aortic valve. Ann. Thorac. Surg. 60(2 Suppl.), S374-S378 (1995).
53. Shi Y, Iyer R, Soundararajan A, Dobkin D, Vesely I: Collagen-based tissue engineering as applied to heart valves. Conf. Proc. IEEE Eng. Med. Biol. Soc. 5, 4912-4915 (2005).
54. Vesely I: The role of elastin in aortic valve mechanics. J. Biomech. 31(2), 115-123 (1998).
55. Stephens EH, Grande-Allen KJ. Age-related changes in collagen synthesis and turnover in porcine heart valves. J. Heart Valve Dis. 16(6), 672-682 (2007).
56. Stephens EH, Chu CK, Grande-Allen KJ. Valve proteoglycan content and glycosaminoglycan fine structure are unique to microstructure, mechanical load and age: relevance to an age-specific tissue-engineered heart valve. Acta Biomater. 4(5), 1148-1160 (2008).
57. Schoen FJ. New frontiers in the pathology and therapy of heart valve disease: 2006 Society for Cardiovascular Pathology, distinguished achievement award lecture. Cardiovasc. Pathol. 15, 271-279 (2006).
58. Mol A, Smits AI, Bouten CV, Baaijens FP: Tissue engineering of heart valves: advances and current challenges. Expert Rev. Med. Devices 6(3), 259-275 (2009).
59. Schoen FJ. Aortic valve structure-function correlations: role of elastic fibers no longer a stretch of the imagination. J. Heart Valve Dis. 6(1), 1-6 (1997).
60. Lee DJ, Steen J, Jordan JE, et al. Endothelialization of heart valve matrix using a computer-assisted pulsatile bioreactor. Tissue Eng. Part A 15(4), 807-814 (2009).
61. El-Hamamsy I, Balachandran K, Yacoub MH, et al. Endothelium-dependent regulation of the mechanical properties of aortic valve cusps. J. Am. Coll. Cardiol. 53(16), 1448-1455 (2009).
62. Schmidt D, Achermann J, Odermatt B, et al. Prenatally fabricated autologous human living heart valves based on amniotic fluid derived progenitor cells as single cell source. Circulation. 116(11 Suppl.), I64-I70 (2007).
63. Liu AC, Joag VR, Gotlieb AI: The emerging role of valve interstitial cell phenotypes in regulating heart valve pathobiology. Am. J. Pathol. 171(5), 1407-1418 (2007).
64. Aikawa E, Whittaker P, Farber M, et al. Human semilunar cardiac valve remodeling by activated cells from fetus to adult - implications for postnatal adaptation, pathology and tissue engineering. Circulation 113, 1344-1352 (2006).
65. Schoen FJ. Evolving concepts of cardiac valve dynamics: the continuum of development, functional structure, pathobiology and tissue engineering. Circulation 118(18), 1864-1880 (2008).
66. Hjortnaes J, Bouten CV, Van Herwerden LA, Grundeman PF, Kluin J. Translating autologous heart valve tissue engineering from bench to bed. Tissue Eng. Part B Rev. 15(3), 307-317 (2009).
67. Rabkin E, Hoerstrup SP, Aikawa M, Mayer JE Jr, Schoen FJ. Evolution of cell phenotype and extracellular matrix in tissue-engineered heart valves during in vitro maturation and in vivo remodeling. J. Heart Valve Dis. 11(3), 308-314; discussion 314 (2002).
68. Rabkin-Aikawa E, Farber M, Aikawa M, Schoen FJ. Dynamic and reversible changes of interstitial cell phenotype during remodeling of cardiac valves. J. Heart Valve Dis. 13(5), 841-847 (2004).
69. Appleton AJ, Appleton CT, Boughner DR, Rogers KA: Vascular smooth muscle cells as a valvular interstitial cell surrogate in heart valve tissue engineering. Tissue Eng. Part A 15(12), 3889-3897 (2009).
70. Sales VL, Mettler BA, Engelmayr GC Jr, et al. Endothelial progenitor cells as a sole source for ex vivo seeding of tissue-engineered heart valves. Tissue Eng. Part A 16(1), 257-267 (2010).
71. Mulholland DL, Gotlieb AI: Cell biology of valvular interstitial cells. Can J. Cardiol. 12(3), 231-236 (1996).
72. Sacks MS, Yoganathan AP: Heart valve function: a biomechanical perspective. Philos. Trans. R Soc. Lond. B Biol. Sci. 362(1484), 1369-1391 (2007).
73. Nakajima Y, Yamagishi T, Hokari S, Nakamura H: Mechanisms involved in valvuloseptal endocardial cushion formation in early cardiogenesis: roles of transforming growth factor (TGF)-b and bone morphogenetic protein (BMP). Anat. Rec. 258(2), 119-127 (2000).
74. Sales VL, Engelmayr GC Jr, Johnson JA Jr, et al. Protein precoating of elastomeric tissue-engineering scaffolds increased cellularity, enhanced extracellular matrix protein production and differentially regulated the phenotypes of circulating endothelial progenitor cells. Circulation 116(11 Suppl.), I55-I63 (2007).
75. Chen YH, Ishii M, Sucov HM, Maxson RE Jr: Msx1 and Msx2 are required for endothelial-mesenchymal transformation of the atrioventricular cushions and patterning of the atrioventricular myocardium. BMC Dev. Biol. 8, 75 (2008).
76. Thiery JP, Sleeman JP: Complex networks orchestrate epithelial- mesenchymal transitions. Nat Rev Mol Cell Biol. 7(2), 131-142 (2006).
77. Krenning G, Moonen JRAJ, van Luyn MJA, Harmsen MC: Vascular smooth muscle cells for use in vascular tissue engineering obtained by endothelial-to- mesenchymal transdifferentiation (EnMT) on collagen matrices. Biomaterials 29(27), 3703-3711 (2008).
78. Engelmayr GC, Salesb VL, Mayer JE, Sacks MS. Cyclic flexure and laminar flow synergistically accelerate mesenchymal stem cell-mediated engineered tissue formation: Implications for engineered heart valve tissues. Biomaterials 27, 6083-6095 (2006).
79. Sodian R, Hoerstrup SP, Sperling JS, et al. Evaluation of biodegradable, three-dimensional matrices for tissue engineering of heart valves. ASAIO J. 46(1), 107-110 (2000). (Pubitemid 30062655)
80. Hoerstrup SP, Sodian R, Sperling JS, Vacanti JP, Mayer JE: New pulsatile bioreactor for in vitro formation of tissue engineered heart valves. Tissue Eng. 6(1), 75-79 (2000).
81. Flanagan TC, Cornelissen C, Koch S, et al. The in vitro development of autologous fibrin-based tissue-engineered heart valves through optimised dynamic conditioning. Biomaterials 28(23), 3388-3397 (2007).
82. Ziegelmueller JA, Zaenkert EK, Schams R, et al. Optical monitoring during bioreactor conditioning of tissue-engineered heart valves. ASAIO J. 56(3), 228-231 (2010).
83. Ramaswamy S, Gottlieb D, Engelmayr GC Jr, et al. The role of organ level conditioning on the promotion of engineered heart valve tissue development in-vitro using mesenchymal stem cells. Biomaterials 31(6), 1114-1125 (2010).
84. Kaasi A, Cestari IA, Stolf NA, et al. A new approach to heart valve tissue engineering: mimicking the heart ventricle with a ventricular assist device in a novel bioreactor. J. Tissue Eng. Regen. Med. DOI: 10.1002/term.315 (2010) (Epub ahead of print).
85. Paruchuri S, Yang JH, Aikawa E, et al. Human pulmonary valve progenitor cells exhibit endothelial/mesenchymal plasticity in response to vascular endothelial growth factor-A and transforming growth factor-b2. Circ. Res. 99(8), 861-869 (2006).
86. Gwanmesia P, Ziegler H, Eurich R, et al. Inhibition of aortic valvular interstitial cell degeneration by ECM modification - implications for heart valve engineering. Tissue Eng. Part A 16(12), 3737-3746 (2010).
87. Paranya G, Vineberg S, Dvorin E, et al. Aortic valve endothelial cells undergo transforming growth factor-b-mediated and non-transforming growth factor-b-mediated transdifferentiation in vitro. Am. J. Pathol. 159(4), 1335-1343 (2001).
88. Dvorin EL, Wylie-Sears J, Kaushal S, Martin DP, Bischoff J. Quantitative evaluation of endothelial progenitors and cardiac valve endothelial cells. Tissue Eng. 9, 487-493 (2003).
89. Chiu YN, Norris RA, Mahler G, Recknagel A, Butcher JT: Transforming growth factor b, bone morphogenetic protein and vascular endothelial growth factor mediate phenotype maturation and tissue remodeling by embryonic valve progenitor cells: relevance for heart valve tissue engineering. Tissue Eng. Part A 16(11), 3375-3383 (2010).
90. Balguid A, Mol A, van Vlimmeren MA, Baaijens FP, Bouten CV. Hypoxia induces near-native mechanical properties in engineered heart valve tissue. Circulation 119(2), 290-297 (2009).
91. Dohmen PM, da Costa F, Yoshi S, et al. Histological evaluation of tissue-engineered heart valves implanted in the juvenile sheep model: is there a need for in-vitro seeding? J. Heart Valve Dis. 15(6), 823-829 (2006).
92. Engler AJ, Sen S, Sweeney HL, Discher DE: Matrix elasticity directs stem cell lineage specification. Cell 126, 677-689 (2006).
93. Yip CY, Chen JH, Zhao R, Simmons CA: Calcification by valve interstitial cells is regulated by the stiffness of the extracellular matrix. Arterioscler. Thromb. Vasc. Biol. 29(6), 936-942 (2009).
94. Elkins RC, Dawson PE, Goldstein S, Walsh SP, Black KS. Decellularized human valve allografts. Ann. Thorac. Surg. 71(5 Suppl.), S428-S432 (2001).
95. OBrien MF, Goldstein S, Walsh S, et al. The SynerGraft valve: a new acellular (nonglutaraldehyde-fixed) tissue heart valve for autologous recellularization first experimental studies before clinical implantation. Semin. Thorac. Cardiovasc. Surg. 11(4 Suppl. 1), 194-200 (1999).
96. Simon P, Kasimir MT, Seebacher G: Early failure of the tissue engineered porcine heart valve Synergraft in pediatric patients. Eur. J. Cardiothorac. Surg. 23, 1002-1006 (2003).
97. Stock UA, Schenke-Layland K: Performance of decellularized xenogeneic tissue in heart valve replacement. Biomaterials 27(1), 1-2 (2006).
98. Wu S, Liu YL, Cui B, Qu XH, Chen GQ: Study on decellularized porcine aortic valve/poly (3-hydroxybutyrate-co-3-hydroxyhexanoate) hybrid heart valve in sheep model. Artif. Organs 31(9), 689-697 (2007).
99. Kasimir MT, Rieder E, Seebacher G, et al. Decellularization does not eliminate thrombogenicity and inflammatory stimulation in tissue-engineered porcine heart valves. J. Heart Valve Dis. 15(2), 278-286 (2006).
100. Rieder E, Seebacher G, Kasimir MT, et al. Tissue engineering of heart valves: decellularized porcine and human valve scaffolds differ importantly in residual potential to attract monocytic cells. Circulation 111(21), 2792-2797 (2005).
101. Grauss RW, Hazekamp MG, Oppenhuizen F, et al. Histological evaluation of decellularised porcine aortic valves: matrix changes due to different decellularization methods. Eur. J. Cardiothorac. Surg. 27(4), 566-571 (2005).
102. van Lieshout MI, Vaz CM, Rutten MC, Peters GW, Baaijens FP: Electrospinning versus knitting: two scaffolds for tissue engineering of the aortic valve. J. Biomater. Sci. Polym. Ed. 17(1-2), 77-89 (2006).
103. Sodian R, Loebe M, Hein A, et al. Application of stereolithography for scaffold fabrication for tissue engineered heart valves. ASAIO J. 48(1), 12-16 (2002).
104. Jain RA: The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices. Biomaterials 21(23), 2475-2490 (2000).
105. Athanasiou KA, Agrawal CM, Barber FA, Burkhart SS. Orthopaedic applications for PLA-PGA biodegradable polymers. Arthroscopy 14(7), 726-737 (1998).
106. Agrawal CM, Ray RB: Biodegradable polymeric scaffolds for musculoskeletal tissue engineering. J. Biomed. Mater. Res. 55(2), 141-150 (2001).
107. Jockenhoevel S, Zund G, Hoerstrup SP, et al. Fibrin gel - advantages of a new scaffold in cardiovascular tissue engineering. Eur. J. Cardiothorac. Surg. 19, 424-430 (2001).
108. Neidert MR, Tranquillo RT: Tissue-engineered valves with commissural alignment. Tissue Eng. 12(4), 891-903 (2006).
109. Nair LS, Bhattacharyya S, Laurencin CT: Development of novel tissue engineering scaffolds via electrospinning. Expert Opin. Biol. Ther. 4(5), 659-668 (2004).
110. Stankus JJ, Guan J, Fujimoto K, Wagner WR: Microintegrating smooth muscle cells into a biodegradable, elastomeric fiber matrix. Biomaterials 27(5), 735-744 (2006).
111. Mano JF, Silva GA, Azevedo HS, et al. Natural origin biodegradable systems in tissue engineering and regenerative medicine: present status and some moving trends. J. R Soc. Interface 4(17), 999-1030 (2007).
112. Yang F, Elisseeff JH: Cartilage tissue engineering. In: Tissue Engineering. Fisher JP, Mikos AG, Bronzino JD (Eds). CRC Press, FL, USA (2007).
113. Saris DB, Mukherjee N, Berglund LJ, et al. Dynamic pressure transmission through agarose gels. Tissue Eng. 6(5), 531-537 (2000).
114. Paul A, Ge Y, Prakash S, Shum-Tim D. Microencapsulated stem cells for tissue repairing: implications in cell-based myocardial therapy. Regen. Med. 4(5), 733-745 (2009).
115. Di Martino A, Sittinger M, Risbud MV. Chitosan: a versatile biopolymer for orthopaedic tissue-engineering. Biomaterials 26(30), 5983-5990 (2005).
116. Paul A, Shum-Tim D, Prakash S. Investigation on PEG integrated alginate-chitosan microcapsules for myocardial therapy using marrow stem cells genetically modified by recombinant baculovirus. Cardiovasc. Eng. Technol. 1(2), 154-164 (2010).
117. Butcher JT, Nerem RM. Porcine aortic valve interstitial cells in three-dimensional culture: comparison of phenotype with aortic smooth muscle cells. J. Heart Valve Dis. 13(3), 478-485; discussion 485-476 (2004).
118. Butcher JT, Penrod AM, Garcia AJ, Nerem RM. Unique morphology and focal adhesion development of valvular endothelial cells in static and fluid flow environments. Arterioscler. Thromb. Vasc. Biol. 24(8), 1429-1434 (2004).
119. Schaefermeier PK, Cabeza N, Besser JC, et al. Potential cell sources for tissue engineering of heart valves in comparison with human pulmonary valve cells. ASAIO J. 55(1), 86-92 (2009).
120. Roy A, Brand NJ, Yacoub MH: Molecular characterization of interstitial cells isolated from human heart valves. J. Heart Valve Dis. 9(3), 459-464 (2000).
121. Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells. Science 284(5411), 143-147 (1999).
122. Deb A, Wang SH, Skelding K, et al. Bone marrow-derived myofibroblasts are present in adult human heart valves. J. Heart Valve Dis. 14(5), 674-678 (2005).
123. Hoerstrup SP, Kadner A, Melnitchouk S, et al. Tissue engineering of functional trileaflet heart valves from human marrow stromal cells. Circulation 106, 143-150 (2002).
124. Asahara T, Murohara T, Sullivan A, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 275(5302), 964-967 (1997).
125. Asahara T, Chen D, Tsurumi Y, et al. Accelerated restitution of endothelial integrity and endothelium-dependent function after phVEGF165 gene transfer. Circulation 94(12), 3291-3302 (1996).
126. Ingram DA, Mead LE, Tanaka H, et al. Identification of a novel hierarchy of endothelial progenitor cells using human peripheral and umbilical cord blood. Blood 104(9), 2752-2760 (2004).
127. Asahara T, Takahashi T, Masuda H, et al. VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J. 18(14), 3964-3972 (1999). (Pubitemid 29335849)
128. Finney MR, Greco NJ, Haynesworth SE, et al. Direct comparison of umbilical cord blood versus bone marrow-derived endothelial precursor cells in mediating neovascularization in response to vascular ischemia. Biol. Blood Marrow Transplant. 12(5), 585-593 (2006).
129. Sodian R, Schaefermeier P, Abegg-Zips S, et al. Use of human umbilical cord blood-derived progenitor cells for tissue-engineered heart valves. Ann. Thorac. Surg. 89(3), 819-828 (2010).
130. Wolbank S, van Griensven M, Grillari-Voglauer R, Peterbauer-Scherb A: Alternative sources of adult stem cells: human amniotic membrane. Adv. Biochem. Eng. Biotechnol. 123, 1-27 (2010).
131. Schmidt D, Achermann J, Odermatt B, et al. Cryopreserved amniotic fluid-derived cells: a lifelong autologous fetal stem cell source for heart valve tissue engineering. J. Heart Valve Dis. 17(4), 446-455; discussion 455 (2008).
132. Schmidt D, Mol A, Breymann C, et al. Living autologous heart valves engineered from human prenatally harvested progenitors. Circulation 114, 125-131 (2006).
133. Sodian R, Lueders C, Kraemer L, et al. Tissue engineering of autologous human heart valves using cryopreserved vascular umbilical cord cells. Ann. Thorac. Surg. 81, 2207-2216 (2006).
134. Schmidt D, Mol A, Odermatt B, et al. Engineering of biologically active living heart valve leaflets using human umbilical cord-derived progenitor cells. Tissue Eng. 12(11), 3223-3232 (2006).
135. Mendelson K, Schoen FJ. Heart valve tissue engineering: concepts, approaches, progress, and challenges. Ann. Biomed. Eng. 34(12), 1799-1819 (2006).
136. Neuenschwander S, Hoerstrup SP: Heart valve tissue engineering. Transplant Immunol. 12, 359-365 (2004).
137. Rabkin-Aikawa E, Mayer JE, Schoen FJ. Heart valve regeneration. Clin. App. Adv. Biochem. Eng. Biotech. 94, 141-179 (2005).
138. Susin FM, Bagno A, Gerosa G: Hydrodynamic performance of heart valve prostheses: open discussion on European Committee for Standardization International Organization for Standardization standard 5840. J. Thorac. Cardiovasc. Surg. 139(5), 1356-1357 (2010).
139. Hiemann NE, Mani M, Huebler M, et al. Complete destruction of a tissue-engineered porcine xenograft in pulmonary valve position after the Ross procedure. J. Thorac. Cardiovasc. Surg. 139(4), e67-e68 (2010).
140. Somers P, Narine K, De Somer F, de Vos F. Sustained release and activation of the growth factor basic fibroblast growth factor from loaded scaffolds in heart valve tissue engineering. Growth Factors 26(5), 293-299 (2008).
141. Koskenvuo JW, Jarvinen V, Parkka JP, Kiviniemi TO, Hartiala JJ. Cardiac magnetic resonance imaging in valvular heart disease. Clin. Physiol. Funct. Imaging 29(4), 229-240 (2009).
142. Schenke-Layland K: Non-invasive multiphoton imaging of extracellular matrix structures. J. Biophotonics 1(6), 451-462 (2008).
143. Shinoka T, Matsumura G, Hibino N, et al. Midterm clinical result of tissue-engineered vascular autografts seeded with autologous bone marrow cells. J. Thorac. Cardiovasc. Surg. 129(6), 1330-1338 (2005).
144. LHeureux N, Dusserre N, Marini A, et al. Technology insight: the evolution of tissue-engineered vascular grafts - from research to clinical practice. Nat. Clin. Pract. Cardiovasc. Med. 4(7), 389-395 (2007).
145. AAMI/ANSI/ISO. Cardiovascular Implants: Cardiac Valve Prostheses (2009) http://webstore.ansi.org/RecordDetail.aspx?s ku=ANSI%2fAAMI%2fISO+5840%3a2005 +%28R2010%29